Immune Thrombocytopenic Purpura - Pipeline Insight, 2021

DelveInsights, Immune Thrombocytopenic Purpura - Pipeline Insight, 2021, report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Immune Thrombocytopenic Purpura pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
Global coverage

Immune Thrombocytopenic Purpura Understanding
Immune Thrombocytopenic Purpura: Overview
Immune Thrombocytopenic Purpura (ITP), also known as idiopathic thrombocytopenic purpura or immune thrombocytopenia, is an autoimmune bleeding disorder characterized by abnormally low levels of blood cells called platelets. The most common symptoms associated with ITP are low platelet count, easy or excessive bruising, superficial bleeding into the skin, mucosal bleeding, blood in urine or stools, and unusual heavy menstrual flow. The risk of developing ITP is more common among young women than men. The diagnosis of ITP is made by physical examination, medical history, and blood test to count the platelets. The tests are done to exclude other causes of thrombocytopenia, including certain medications or disorders that affect the bone marrow and reduce platelet production, such as acute leukemia and aplastic anemia. Treatment for ITP is based on the degree of bleeding occur and the platelet count. First-line treatments for ITP are corticosteroids and intravenous immunoglobulin (IVIG). Second-line treatments include splenectomy, thrombopoietin analogues, and monoclonal antibodies.

"Immune Thrombocytopenic Purpura - Pipeline Insight, 2021" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Immune Thrombocytopenic Purpura pipeline landscape is provided which includes the disease overview and Immune Thrombocytopenic Purpura treatment guidelines. The assessment part of the report embraces, in depth Immune Thrombocytopenic Purpura commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Immune Thrombocytopenic Purpura collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Immune Thrombocytopenic Purpura R&D. The therapies under development are focused on novel approaches to treat/improve Immune Thrombocytopenic Purpura.

Immune Thrombocytopenic Purpura Emerging Drugs Chapters
This segment of the Immune Thrombocytopenic Purpura report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Immune Thrombocytopenic Purpura Emerging Drugs
Rozanolixizumab: UCB
Rozanolixizumab is an investigational humanized monoclonal antibody that specifically binds to human neonatal Fc receptor (FcRn). It has been designed to block the interaction of FcRn and IgG, inhibiting IgG recycling and inducing the removal of pathogenic IgG autoantibodies. The drug is in Phase III clinical studies for the treatment of immune thrombocytopenia.

Mezagitamab: Takeda
Mezagitamab (also known as TAK-079) is a fully human, IgG1 monoclonal antibody targeting CD38. CD38 is a cell surface molecule that is highly expressed on myeloma cells, plasma cells, plasmablasts, and natural killer (NK) cells, and is induced on activated T cells and other suppressor cells including regulatory T (Tregs) and B (Bregs) cells. The drug is in Phase II clinical studies for the treatment of immune thrombocytopenic purpura.
Further product details are provided in the report..

Immune Thrombocytopenic Purpura: Therapeutic Assessment
This segment of the report provides insights about the different Immune Thrombocytopenic Purpura drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Immune Thrombocytopenic Purpura
There are approx. 18+ key companies which are developing the therapies for Immune Thrombocytopenic Purpura. The companies which have their Immune Thrombocytopenic Purpura drug candidates in the most advanced stage, i.e. Phase III include, UCB.

Phases
DelveInsights report covers around 18+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration
Immune Thrombocytopenic Purpura pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Parenteral
Intravitreal
Subretinal
Topical

Molecule Type
Products have been categorized under various Molecule types such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Immune Thrombocytopenic Purpura: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Immune Thrombocytopenic Purpura therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Immune Thrombocytopenic Purpura drugs.

Immune Thrombocytopenic Purpura Report Insights
Immune Thrombocytopenic Purpura Pipeline Analysis
Therapeutic Assessment
Unmet Needs
Impact of Drugs

Immune Thrombocytopenic Purpura Report Assessment
Pipeline Product Profiles
Therapeutic Assessment
Pipeline Assessment
Inactive drugs assessment
Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
How many companies are developing Immune Thrombocytopenic Purpura drugs?
How many Immune Thrombocytopenic Purpura drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Immune Thrombocytopenic Purpura?
What are the key collaborations (IndustryIndustry, IndustryAcademia), Mergers and acquisitions, licensing activities related to the Immune Thrombocytopenic Purpura therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for Immune Thrombocytopenic Purpura and their status?
What are the key designations that have been granted to the emerging drugs?

Key Players
Cour Pharmaceutical
Hutchison MediPharma
UCB Biopharma
Takeda
Genosco
Sanofi
Principia Biopharma (Sanofi)
argenx

Key Products
CNP-ITP
HMPL 523
Rozanolixizumab
Mezagitamab
Cevidoplenib
SAR-445088
Rilzabrutinib
Efgartigimod

Introduction
Executive Summary
Immune Thrombocytopenic Purpura: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Immune Thrombocytopenic Purpura DelveInsights Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Rozanolixizumab: UCB Biopharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Mid Stage Products (Phase II)
Comparative Analysis
Mezagitamab: Takeda
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Early Stage Products (Phase I)
Comparative Analysis
HMPL-523: Hutchison MediPharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
CNP-ITP: Cour Pharmaceutical
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Inactive Products
Comparative Analysis
Immune Thrombocytopenic Purpura Key Companies
Immune Thrombocytopenic Purpura Key Products
Immune Thrombocytopenic Purpura- Unmet Needs
Immune Thrombocytopenic Purpura- Market Drivers and Barriers
Immune Thrombocytopenic Purpura- Future Perspectives and Conclusion
Immune Thrombocytopenic Purpura Analyst Views
Appendix

List Of Tables

Table 1 Total Products for Immune Thrombocytopenic Purpura
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products

List Of Figures

Figure 1 Total Products for Immune Thrombocytopenic Purpura
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Immune Thrombocytopenia (ITP) Market in China 2023

Immune thrombocytopenia (ITP) is a rare autoimmune disorder that affects the bloods ability to clot properly. It is caused by the immune system mistakenly attacking and destroying platelets, which are

USD 675 View Report

Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021

Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Primary Immune Deficiency (PID) (Genitourinary Disorders) - Drugs In Development,

USD 2000 View Report

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H2 2020

Thrombotic Thrombocytopenic Purpura (Moschcowitz Disease) - Pipeline Review, H2 2020latest Pharmaceutical and Healthcare disease pipeline guide Thrombotic Thrombocytopenic Purpura - Pipeline Review, H2 2020, provides an overview of the Thrombotic

USD 2000 View Report

Acquired Thrombotic Thrombocytopenic Purpura - Market Insight, Epidemiology and Market Forecast - 2030

Acquired Thrombotic Thrombocytopenic Purpura - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Acquired Thrombotic Thrombocytopenic Purpura, historical and forecasted epidemiology as well as the

USD 6950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available